MIDDLEBROOK PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Three Months Ended March 31,
2008 2007
Cash flows from operating activities:
Net loss $(13,799,502) $(13,662,990)
Adjustments to reconcile net loss
to net cash in operating
activities:
Loss attributable to non-
controlling interest (242,905) -
Depreciation and amortization 940,635 951,897
Warrant expense 7,440,000 -
Stock-based compensation 537,735 580,711
Deferred rent and credit on
lease concession (26,667) (11,661)
Amortization of premium on
marketable securities - 8,953
Loss on disposal of fixed assets 19,074 -
Changes in:
Accounts receivable (77,216) (763,807)
Inventories 314,609 (87,862)
Prepaid expenses and other
current assets 348,648 47,891
Deposits other than on
property and equipment, and
other assets 42,641 194,087
Accounts payable 461,659 4,763,592
Accrued expenses (923,332) (270,989)
Net cash used in
operating activities (4,964,621) (8,250,178)
'/>"/>| SOURCE MiddleBrook Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |